Abstract: Described herein are reprogrammed cells, and methods for cell dedifferentiation, transformation and eukaryotic cell reprogramming. Also described are cells, cell lines, and tissues that can be transplanted in a patient after steps of in vitro dedifferentiation and in vitro reprogramming. In particular embodiments the cells are Stem-Like Cells (SLCs), including Neural Stem-Like Cells (NSLCs), Cardiac Stem-Like Cells (CSLC), Hematopoietic Stem-Like Cells (HSLC), Pancreatic Progenitor-Like Cells, and Mesendoderm-like Cells. Also described are methods for generating these cells from human somatic cells and other types of cells. Also provided are compositions and methods of using of the cells so generated in human therapy and in other areas.
Abstract: The present invention relates to a protein having glucose dehydrogenase activity selected from:(a) an amino acid sequence represented by SEQ ID NO: 3; (b) an amino acid sequence in which 1 to 3 amino acids are deleted from, replaced in or added to the amino acid sequence represented by SEQ ID NO: 3;(c) an amino acid sequence which has at least 80% identity with the amino acid sequence represented by SEQ ID NO: 3 and whose N-terminus is SS; or(d) an amino acid sequence which has at least 80% identity with the amino acid sequence represented by SEQ ID NO: 3, and does not contain a sequence represented by SEQ ID NO: 8 at its N-terminus. The invention also includes a polynucleotide encoding the enzyme, a method for manufacturing the enzyme, a method for measuring glucose using the enzyme, a measuring reagent composition and a biosensor.
Abstract: The invention relates to an unspecific peroxygenase of the Agrocybe aegerita fungus, obtained by means of directed molecular evolution to facilitate the functional expression thereof in an active, soluble and stable form. The peroxygenase described in the invention shows a significant improvement in the functional expression thereof, improved monooxygenase activity and reduced peroxidase activity, in relation to the monooxygenase and peroxidase activities showed by the unspecific wild-type peroxygenase of A. aegerita. The peroxygenase of the invention is useful in chemical processes, including industrial transformations such as the selective oxyfunctionalisation of carbon-hydrogen bonds of various organic compounds.
Type:
Application
Filed:
November 14, 2016
Publication date:
January 24, 2019
Applicant:
CONSEJO SUPERIOR INVESTIGACIONES CIERNTIFICAS (CSIC)
Inventors:
Patricia MOLINA ESPEJA, Francisco José PLOU GASCA, Miguel ALCALDE GALEOTE, Patricia GÓMEZ DE SANTOS
Abstract: The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.
Type:
Application
Filed:
October 5, 2018
Publication date:
January 24, 2019
Inventors:
Robert Osborne, Vesna Mitchell, Khin Yu Naing Htwe, Xiyun Zhang, Erika M. Milczek, Jeffrey C. Moore
Abstract: The present application relates to a microorganism of the genus Corynebacterium having L-isoleucine producing ability which comprises a protein having an activity of citramalate synthase, and a method for producing L-isoleucine using the same.
Type:
Application
Filed:
October 21, 2016
Publication date:
January 24, 2019
Inventors:
Su Yon Kwon, Jae Woo Jang, Min Se Kim, Ju Jeong Kim
Abstract: A bacteriophage RNA polymerase variant is provided. In some embodiments, the variant may have increased thermostability relative to the corresponding wild type bacteriophage RNA polymerase and/or wild type T7 RNA polymerase. Compositions, kits and methods that employ the variant are also provided.
Type:
Application
Filed:
January 12, 2017
Publication date:
January 24, 2019
Applicant:
New England Biolabs, Inc.
Inventors:
Jennifer Ong, Shaorong Chong, Haruichi Asahara, Kuo-Chan Hung, Vladimir Potapov, George Tzertzinis
Abstract: The invention relates to improved alkaline phosphatases, pharmaceutical compositions comprising improved alkaline phosphatases and the use of improved alkaline phosphatases for preventing, treating or curing diseases.
Type:
Application
Filed:
February 7, 2018
Publication date:
January 24, 2019
Applicant:
AM-Pharma B.V.
Inventors:
Willem RAABEN, Luigi Johannes Cornelius JONK, Erik Jan VAN DEN BERG, Andrea VAN ELSAS, José Luis MILLÁN
Abstract: The present invention relates to isolated polypeptides having phospholipase C activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: The present invention provides lipolytic enzyme variants. Specifically, the present invention provides lipolytic enzyme variants having one or more modifications as compared to a parent lipolytic enzyme having at least one improved property. In addition, the present invention provides compositions comprising a lipolytic enzyme variant of the invention. The present invention also provides methods of cleaning using compositions comprising a lipolytic enzyme variant of the invention.
Type:
Application
Filed:
October 9, 2018
Publication date:
January 24, 2019
Inventors:
Thomas P. Graycar, David A. Estell, Ayrookaran J. Poulose, Sina Pricelius
Abstract: The present invention relates to a non-viral method for transfecting a hematopoietic cell which can be employed in immunotherapy. This method is based on the use of nanoparticle-biomolecule conjugates with increased homologous recombination. Nucleic acid to be transfected can be a chimeric antigen receptor and/or encoding a target-specific endonuclease. The present invention relates also to a method for transfecting APCs. Furthermore, the present invention relates to pharmaceutical compositions, uses and kits.
Abstract: The present application relates to the field of glyco-engineering, more specifically to glyco-engineering of Fc-containing molecules, such as antibodies. It is shown herein that Fc-containing molecules with a specific glycosylation pattern have a considerably longer circulating half-life in vivo, without having an altered binding affinity for their respective antigen. This has therapeutic implications in reducing the frequency with which these molecules need to be administered, without affecting therapeutic efficacy. Also, cells are provided that can produce the Fc molecules with the desired glycosylation pattern.
Abstract: The invention relates to a variant of a parent Termamyl-like alpha-amylase, which variant exhibits altered properties, in particular reduced capability of cleaving a substrate close to the branching point, and improved substrate specificity and/or improved specific activity relative to the parent alpha-amylase.
Type:
Application
Filed:
September 24, 2018
Publication date:
January 24, 2019
Applicant:
NOVOZYMES A/S
Inventors:
Carsten Andersen, Christel Thea Jorgensen, Henrik Bisgaard-Frantzen, Allan Svendsen, Soren Kjaerulff
Abstract: The present invention relates to compositions comprising an aglycosylated polypeptide having cellobiase activity, and methods for producing and using the same.
Type:
Application
Filed:
October 4, 2018
Publication date:
January 24, 2019
Inventors:
Marshall Medoff, Natasha Kreder, James J. Lynch, Sean Landry, Aiichiro Yoshida, Desiree Pangilinan, Thomas Craig Masterman
Abstract: The present invention relates to a heat-resistant agarase and a monosaccharide production method using same. More particularly, in the present invention, a heat-resistant agarase may be used to produce galactose and 3,6-anhydro-L-galactose at high yield by efficiently breaking down agarose or agar without a chemical pretreatment, a neutralization process, or an agarotriose hydrolase treatment process.
Type:
Application
Filed:
January 17, 2017
Publication date:
January 24, 2019
Applicant:
Korea University Research and Business Foundation
Inventors:
Kyoung Heon KIM, In-Geol CHOI, Jung Hyun KIM, Eun-Ju YUN
Abstract: Compositions and methods for targeted treatment of cancer are disclosed. In particular, the invention relates to methods of targeting anti-cancer therapy to cells exhibiting aberrant signaling associated with cancer pathogenesis by administering synthetic signaling proteins that couple detection of an oncogenic signal to release of therapeutic agents into cancerous cells.
Abstract: The present invention concerns a construct for epigenomic modification of genes that includes the following components: a) a Krüppel-associated box zinc finger protein or homologous, b) a DNA region capable of binding to the target gene or homologous, c) a human DNA methyltransferase DNMT3A or homologous and d) a murine DNA methyltransferase Dnmt3L or homologous whereby components a), b), c) and d) are linked to each other either directly or via at least one linker. The construct is a designer epigenome modifier which can be used to silence genes coding for a protein in leukocytes which avoids the internalization of HI viruses in immune cells.
Type:
Application
Filed:
July 24, 2017
Publication date:
January 24, 2019
Applicant:
Albert-Ludwigs-Universitaet Freiburg
Inventors:
Toni CATHOMEN, Claudio MUSSOLINO, Tatjana I. CORNU, Tafadzwa MLAMBO, Sandra NITSCH, Jamal ALZUBI, Marianna ROMITO
Abstract: Provided herein, in some embodiments, are nucleic acid-based tools that may be used for high-throughput functional genomics studies as well as for the generation of knockout (gene inactivation or deletion) or knockin (gene activation or insertion) cell lines. Tools of the present disclosure include an “activatable reporter cassette,” a guide RNA construct and a nuclease that can be used together, for example, to modify and isolate targeted cells of interest.
Type:
Application
Filed:
January 13, 2017
Publication date:
January 24, 2019
Inventors:
Marcello MARESCA, Amir TAHERI-GHAHFAROKHI, Mohammad BOHLOOLY-YEGANEH, Lorenz M. MAYR
Abstract: Provided herein are methods and compositions for the detection and identification of targets in a sample, using target-specific guide nucleic acids and nucleic acid-guided nuclease system proteins.
Type:
Application
Filed:
February 23, 2017
Publication date:
January 24, 2019
Inventors:
Stephane B. GOURGUECHON, Meredith L. CARPENTER, Eric HARNESS
Abstract: Disclosed are methods and devices for lysing cells to release extract genomic DNA (gDNA). The methods use a mixture of microscopic glass beads and cells (for example, spores) that form a semi-dry cake that clings to a larger metal ball and the sides of the tube during bead beating lysis, greatly improving the efficiency of the bead beating process. The devices produce a chaotic motion which ensures that sufficient force is generated to open the cells, and that the metal ball impacts are distributed across the interior surface of the container so that all of the cell mixture is subjected to sufficient impacts to break the cells. As a result, spores and other difficult-to-lyse microbes, can be opened in seconds. The method reduces the number of steps and hands-on time by rapidly opening difficult to lyse cells, while preserving the integrity of the DNA.
Type:
Application
Filed:
July 16, 2018
Publication date:
January 24, 2019
Inventors:
Mark Driscoll, Thomas Jarvie, Ryan Beach, Jeff Whynall
Abstract: The disclosure generally relates to compositions and methods for the extraction of nucleic acids from biological samples. In particular embodiments the extraction involves the use of an organic solvent with sufficient density so that centrifugation of the sample is not needed to achieve phase separation.
Abstract: Methods of generating conditionally active biologic proteins, in particular therapeutic or diagnostic proteins, which are more active at an aberrant condition than at a normal physiological condition. The methods include discovery methods using libraries of proteins and assays employing physiological concentrations of components of bodily fluids. The conditionally active biologic proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety. Criteria for selecting starting proteins for the discovery methods, as well as formats of the proteins are also disclosed.
Type:
Application
Filed:
February 24, 2016
Publication date:
January 24, 2019
Applicant:
BIOATLA, LLC
Inventors:
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Abstract: A product and process for extending the replicative capacity of metazoan somatic cells using targeted genetic amendments to abrogate inhibition of cell-cycle progression during replicative senescence and derive clonal cell lines for scalable applications and industrial production of metazoan cell biomass. An insertion or deletion mutation using guide RNAs targeting the first exon of the transcript encoding each protein is created using CRISPR/Cas9. Targeted amendments result in inactivation of p15 and p16 proteins which increases the proliferative capacity of the modified cell populations relative to their unaltered parental populations. Combining these amendments with ancillary telomerase activity from a genetic construct directing expression of a telomerase protein homolog from a TERT gene, increases the replicative capacity of the modified cell populations indefinitely.
Type:
Application
Filed:
January 17, 2017
Publication date:
January 24, 2019
Inventors:
Nicholas J. GENOVESE, Danielle Nicole DESMET, Eric SCHULZE
Abstract: Disclosed herein are compositions and methods for attenuating detoxification response and related symptoms thereof induced by translation defect. The compositions and methods herein are useful for attenuating detoxification response and/or treat related symptoms thereof in subjects comprising translation defect. The composition and methods herein are also useful for improving pharmacokinetics of a pharmaceutical compound.
Abstract: Subjects of the invention are: nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interference in eukaryotic host and use of nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG-type repeats. Solution relates to the new concept of treating hereditary human neurological diseases caused by expansion of CAG-type trinucleotide repeats using RNA interference technology.
Type:
Application
Filed:
April 16, 2018
Publication date:
January 24, 2019
Inventors:
Wlodzimierz KRZYZOSIAK, Marta OLEJNICZAK, Paulina GALKA-MARCINIAK, Agnieszka FISZER
Abstract: Provided are compositions and methods comprising two-tailed siRNAs (tt-siRNAs) that exhibit unprecedented cellular uptake and silencing. Also provided are methods of treating neurological and other diseases with the two-tailed siRNAs of the invention.
Type:
Application
Filed:
June 22, 2018
Publication date:
January 24, 2019
Inventors:
Anastasia Khvorova, Julia Alterman, Matthew Hassler
Abstract: The present invention relates to methods for shifting the splicing profile of the DUX4 gene, a double homeobox gene on human chromosome 4q35. Recombinant adeno-associated viruses of the invention deliver DNAs encoding U7-based small nuclear RNAs to induce DUX4 exon-skipping and the expression of shortened forms of DUX4. The methods have application in the treatment of muscular dystrophies such as facioscapulohumeral muscular dystrophy.
Abstract: The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders associated with the expression of FLG.
Type:
Application
Filed:
September 28, 2018
Publication date:
January 24, 2019
Inventors:
Joseph Collard, Olga Khorkova Sherman, Carlos Coito
Abstract: Disclosed herein are compositions comprising extracellular vesicles, such as exosomes, displaying an RNA nanoparticle on its surface. The RNA nanoparticle can target the extracellular vesicle to a given cell via a targeting moiety. The extracellular vesicle can also comprise a functional moiety, which can be used in treatment or diagnostics.
Type:
Application
Filed:
October 5, 2018
Publication date:
January 24, 2019
Inventors:
Peixuan Guo, Fengmei Pi, Hui Li, Shaoying Wang
Abstract: Described herein are aptamers capable of binding to growth differentiation factor 11 (GDF11) protein; compositions comprising a GDF11 binding aptamer with a GDF11 protein; and methods of making and using the same.
Type:
Application
Filed:
November 23, 2015
Publication date:
January 24, 2019
Applicant:
SOMALOGIC, INC.
Inventors:
Urs OCHSNER, Louis GREEN, Dom ZICHI, Nebojsa JANJIC
Abstract: The invention relates to polynucleotide agents targeting Factor XII (F12) gene, and methods of using such polynucleotide agents to inhibit expression of Factor XII and to treat subjects having a Factor XII-associated disease, e.g., heredity angioedema (HAE), prekallikrein deficiency, malignant essential hypertension, hypertension, end stage renal disease, or Fletcher Factor Deficiency.
Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
Type:
Application
Filed:
September 5, 2018
Publication date:
January 24, 2019
Applicant:
Silence Therapeutics GMBH
Inventors:
Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
Abstract: The present invention concerns a construct for epigenomic modification of genes comprising the following components: a) a Krüppel-associated box zinc finger protein or homologous, b) a DNA region capable of binding to the target gene or homologous, c) a human DNA methyltransferase DNMT3A or homologous and d) a murine DNA methyltransferase Dnmt3L or homologous whereby components a), b), c) and d) are linked to each other either directly or via at least one linker. The construct is a designer epigenome modifier which can be used to silence genes coding for a protein in leukocytes which avoids the internalization of HI viruses in immune cells.
Type:
Application
Filed:
April 11, 2018
Publication date:
January 24, 2019
Applicant:
Albert-Ludwigs-Universitaet Freiburg
Inventors:
Toni CATHOMEN, Claudio MUSSOLINO, Tatjana I. CORNU, Tafadzwa MLAMBO, Sandra NITSCH, Jamal ALZUBI, Marianna ROMITO
Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
Type:
Application
Filed:
January 6, 2017
Publication date:
January 24, 2019
Inventors:
Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
Abstract: Provided are a microorganism having activity in reducing a concentration of a fluorine-containing compound in a sample, a recombinant microorganism including a gene derived from the microorganism, and a method of reducing the concentration of the fluorine-containing compound in the sample by using the microorganism or recombinant microorganism.
Type:
Application
Filed:
July 24, 2018
Publication date:
January 24, 2019
Inventors:
Yukyung Jung, Jongwon Byun, Taeyong Kim, Jinhwan Park, Seunghoon Song
Abstract: The present invention relates to a recombinant microorganism having the ability to produce poly(lactate-co-glycolate) and its copolymers from xylose, and more particularly to a recombinant microorganism having the ability to produce poly(lactate-co-glycolate) and its copolymers without having to supply a glycolate precursor from an external source, and a method of producing a poly(lactate-co-glycolate) copolymers using the same.
Type:
Application
Filed:
December 13, 2016
Publication date:
January 24, 2019
Inventors:
Sang Yup Lee, So Young Choi, Si Jae Park
Abstract: A peptide comprising the sequence shown below is added as a peptide tag to a useful protein, followed by allowing its expression. Xm(PYn)qPZr In this formula, X, Y, and Z each represent an amino acid residue independently selected from the group consisting of R, G, S, K, T, L, N, Q, and H, with the proviso that at least one Y represents K, L, N, Q, H, or R. m represents an integer of 0 to 5; n represents 1, 2, or 3; q represents an integer of 1 to 10; and r represents an integer of 0 to 10.
Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.
Abstract: The invention relates to a process for the in vivoproduction of a target RNA in a host cell comprising providing a microorganism comprising a vector comprising a DNA sequence encoding the target RNA, fermenting the host cell and allowing the DNA sequence to be transcribed into the target RNA, and obtaining the target RNA from the host cell. The process is characterised in that the host cell comprises a vector comprising a DNA sequence encoding an RNase inhibitor. The invention also relates to the vector used in such process and the host cell comprising such vector as well as the use of the vector and the host cell in such process.
Type:
Application
Filed:
August 7, 2015
Publication date:
January 24, 2019
Inventors:
Andreas SCHMID, Isabel STROBEL, Fabian Johannes EBER
Abstract: The present invention relates to a Plasmid Addiction System for the stabilization of expression plasmids encoding proteins of interest. The invention uses a succinate cycle optimization to ensure the expression of plasmid(s) of interest. By ensuring that plasmids of interest contain genes necessary in the succinate cycle, the system ensures that the passage of the plasmid to daughters and therefore improves the efficiency of production and expression of genes and/or products of interest.
Type:
Application
Filed:
July 16, 2018
Publication date:
January 24, 2019
Applicant:
Conagen Inc.
Inventors:
Matthew de la Pena Mattozzi, Daniel Kim, Sonya Clarkson
Abstract: The present invention provides a method of modifying a targeted site of a double stranded DNA in a host cell, the method including introducing (a) a DNA encoding a crRNA containing a sequence complementary to a target strand of a target nucleotide sequence in the given double stranded DNA, and (b) a DNA encoding a protein group constituting Cascade and a nucleic acid base converting enzyme, in which the nucleic acid base converting enzyme is constituted in a form capable of forming a complex with any protein in the protein group, into the host cell to convert one or more nucleotides in the targeted site to other one or more nucleotides, or delete one or more nucleotides, or insert one or more nucleotides into said targeted site, without cleaving the double stranded DNA in the targeted site.
Type:
Application
Filed:
September 8, 2016
Publication date:
January 24, 2019
Applicant:
NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
Abstract: As disclosed herein, optimal native genomic loci from maize plants have been identified that represent best sites for targeted insertion of exogenous sequences.
Type:
Application
Filed:
August 24, 2018
Publication date:
January 24, 2019
Inventors:
Lakshmi Sastry-Dent, Zehui Cao, Shreedharan Sriram, Steven R. Webb, Debra L. Camper
Abstract: The present application relates to an expression system for multigene overexpression in microalgae, which expression system comprises at least two nucleic acid expression cassettes, wherein each expression cassette comprises a promoter operably linked to three or more transgenes connected to one another by at least one sequence encoding a 2A peptide (i.e. a multicistronic construct). Also disclosed herein are vector systems comprising said expression systems, host cells transformed with said expression systems or comprising said vector systems, methods for producing these host cells, as well as their use for biosynthesis.
Type:
Application
Filed:
January 27, 2017
Publication date:
January 24, 2019
Inventors:
Séverine COLLIN, Laurent FOURAGE, Fédéric LAEUFFER, Mariette BEDHOMME, Leonardo MAGNESCHI, Giovanni FINAZZI, Eric MARECHAL
Abstract: Genetic male sterile plants are provided in which complementing constructs result in suppression of a parental phenotype in the progeny. Methods to generate and maintain such plants and methods of use of said plants, are provided, including use of parental plants to produce sterile plants for hybrid seed production.
Type:
Application
Filed:
August 30, 2017
Publication date:
January 24, 2019
Applicant:
PIONEER HI-BRED INTERNATIONAL, INC.
Inventors:
TIM FOX, DALE F. LOUSSAERT, JEFFREY SCHUSSLER, JUAN PABLO SAN MARTIN TOLOZA, BO SHEN
Abstract: Materials and methods are provided for making soybean varieties that have altered oil composition as a result of mutations in the FAD3A, FAD3B, and FAD3C genes.
Type:
Application
Filed:
August 2, 2018
Publication date:
January 24, 2019
Inventors:
Luc Mathis, Zachary Demorest, Feng Zhang, William Haun
Abstract: Methods and compositions for producing epidermal growth factor (EGF) in soybean seeds featuring the use of transgenic soybean seeds expressing a seed-specific codon optimized gene encoding of the hEGF protein. Using these methods, the production of hEGF is sufficient and the activity of the EGF protein is comparable to commercially available EGF. The present invention shows the feasibility of using soybean seeds as a biofactory to produce therapeutic agents for a delivery platform, e.g., in a soymilk delivery platform.
Type:
Application
Filed:
June 18, 2018
Publication date:
January 24, 2019
Inventors:
Eliot Herman, Monica Schmidt, Brad W. Warner
Abstract: Increased antigenicity of a membrane-bound polypeptide produced from a plant is provided in a process in which extraction of the polypeptide or other compounds from the plant is such that phospholipids are associated with the polypeptide. Reducing fat by supercritical fluid extraction increases antigenicity of such plant-produced membrane-bound polypeptides. Methods and means of producing such membrane-bound polypeptides are provided. Methods to produce a protective response in animals are provided by administering to the animal the membrane-bound polypeptide. Binding of antibody specific to the membrane-bound polypeptide is increased. The process provides for increased preferred formation of the membrane-bound polypeptide. Stability of the membrane-bound polypeptide is increased when the plant material is defatted.
Type:
Application
Filed:
October 10, 2018
Publication date:
January 24, 2019
Inventors:
John Howard, Celine Hayden, Rafael Jimenez-Flores